Insights
Insights From Our Experts
Articles
Next-Generation Brand Planning: Some (Unexpected) Worrying Trends Demand a Rethink on Brand Planning
In our third annual report on the state of brand planning, EVERSANA surveyed nearly 100 brand planning executives across biopharmaceuticals, diagnostics and medical devices. This year, we expanded our assessment by hosting 111 marketing leaders from…
The AI Revolution: 7 Trends Shaping the AI Revolution in 2025
We’re just weeks into 2025, and already, the landscape of artificial intelligence (AI) continues to evolve at an unprecedented pace, reshaping industries and redefining possibilities. In the realm of healthcare, AI is not just a buzzword;…
Point-of-Care (POC) Diagnostics: Transformation From Pre- to Post- Pandemic: An Asian Perspective
Authors: Dr. Shaillender M, Engagement Manager, EVERSANA APAC; Robin Arnold, Executive Vice President, EVERSANA APAC; Aditya Prakash, Consultant, EVERSANA APAC The pandemic significantly accelerated the adoption and technological advancement of point-of-care (POC) diagnostics, transforming them from…
The Evolution of Digital Health Policy: A 2024 Retrospective and 2025 Outlook
The landscape of digital health policy continues to evolve, with significant advancements shaping the regulatory and reimbursement frameworks. Here are some of the key developments that occurred during 2024 as well as our predictions for what…
Beyond Theory: Integrated Commercialization Model Proves Valuable in Launch Success
Unlock the Future of Drug Commercialization Discover the Proven Strategies Behind Successful Drug Launches Are you ready to revolutionize your drug commercialization approach? Download our exclusive whitepaper, “Beyond Theory: Integrated Commercialization Model Proves Valuable in Launch Success,” and…
Think Tank 2025 Pharma Forecast: What Lies Ahead for the Industry in 2025?
The pharmaceutical industry is poised for a transformative evolution by 2025, driven by the possibilities of emerging technologies, regulatory shifts, personalized medicine, and lessons from recent global crises. Together, these trends will redefine the pharmaceutical landscape,…
Evaluating PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Matching-Adjusted Indirect Comparison
Posted by
Imtiaz Samjoo , Anja Haltner, MSc , Samantha Craigie , Di Wang , Sarah Walsh on December 19, 202412/19/24
Metastatic castration-resistant prostate cancer (mCRPC) is an incurable condition associated with poor prognosis and quality of life. Historically, patients with mCRPC had limited therapeutic options, and despite advancements in therapeutic innovation, the five-year relative survival rate…
From Challenges to Solutions: Breaking Barriers to Revolutionize Patient Services
Patients today too often find themselves navigating a myriad of challenges that can make accessing quality healthcare a daunting task. Various common obstacles range from financial barriers to long wait times, to geographical and technological limitations…
Association Between Targeted Therapy and Survival in Patients with Myelodysplastic Syndromes
Posted by
Pierantonio Russo, MD, FCPP, FAAP, STS , Ramaa Nathan, PhD , Alex Moore, PhD , Daniel Pfeffer, PhD on December 10, 202412/10/24
Precision oncology offers a new approach to cancer care by providing targeted treatments for patients with actionable genetic mutations. However, in the U.S., nearly one-third of eligible patients face barriers such as delayed test results, limited…
Association Between Targeted Therapy and Survival in Patients With Acute Myeloid Leukemia
Posted by
Pierantonio Russo, MD, FCPP, FAAP, STS , Ramaa Nathan, PhD , Alex Moore, PhD , Daniel Pfeffer, PhD on December 9, 202412/9/24
Precision oncology innovatively addresses cancer care by targeting treatments to patients with specific biomarker alterations. However, in the U.S., nearly one-third of eligible patients miss out on these life-saving therapies. Operational barriers, physician awareness gaps, slow…